Dexmedetomidine pharmacokinetics in the obese
- 26 September 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 71 (12), 1501-1508
- https://doi.org/10.1007/s00228-015-1948-2
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- CYP2A6 genetic variation and dexmedetomidine dispositionEuropean Journal of Clinical Pharmacology, 2012
- Determination of dexmedetomidine in human plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection: Application to a pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2009
- Regio- and Stereospecific N-Glucuronidation of Medetomidine: The Differences between UDP Glucuronosyltransferase (UGT) 1A4 and UGT2B10 Account for the Complex Kinetics of Human Liver MicrosomesPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2008
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- A Standard Weight Descriptor for Dose Adjustment in the Obese PatientClinical Pharmacokinetics, 2004
- Cardiac function during laparoscopic vs open gastric bypassSurgical Endoscopy, 2001
- Postoperative Pharmacokinetics and Sympatholytic Effects of DexmedetomidineAnesthesia & Analgesia, 1997
- Postoperative Pharmacokinetics and Sympatholytic Effects of DexmedetomidineAnesthesia & Analgesia, 1997
- Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical AccuracyStatistical Science, 1986
- Drug Pharmacokinetics in the Postoperative PeriodClinical Pharmacokinetics, 1979